

Special Issue

Precision Medicine Genomics: Pharmacogenomics

Message from the Guest Editors

The history of healthcare is going through a period of transformation. The concept of "precision medicine" concerns the prevention, diagnosis and treatment of diseases by taking into account the genomic and molecular characteristics of each patient. Traditionally, the selection of a particular drug for pharmacological prescription has been decided by trial and error. However, an increasing amount of information is becoming available to increase efficacy and prevent adverse drug reactions based on pharmacogenomics. Pharmacogenomics is the main tool of precision medicine that uses genetic/omics information to individualize prescriptions in order to optimize drug response. In this way, the efficacy of these therapies would be maximized, reducing side effects and also the unnecessary costs associated with treatment failure and hospitalizations due to adverse drug reactions, thus improving patients' quality of life. However, since precision medicine remains a challenge, the aim of this issue is to collect solid articles from any field of personalized medicine or genomics that will increase the knowledge of precision medicine.

Guest Editors

Dr. Luis Andrés López-Fernández

Dr. Sara Salvador-Martín

Dr. Matea Zajc Petranović

Deadline for manuscript submissions

closed (15 September 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/111968

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).